About

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on.

With the agility of a virtual business but the reassurance that comes with a heritage spanning decades, smart thinking, innovation and a passion for enhancing medicines to broaden access and improve patient health outcomes is at the heart of our business. This is reflected in the work we do, how we do it and the people who deliver it.

As the go to partner for commercialising complex medicines in European hospitals, our agile and highly experienced teams in marketing, direct sales, market access and medical work across major European markets to broaden access, choice and availability while our established products business with its portfolio of more than 180 molecules provides essential medicines globally to the patients that need them.

Download the ADVANZ PHARMA® Corporate Brochure


Our locations

ADVANZ PHARMA has an operational headquarters in London, an operations centre of excellence in Mumbai, offices in Geneva and Paris and commercial affiliates in North America, Europe and Australia/NZ, together with an established global network of commercial partners throughout the rest of the world

Our Locations —

  • London —

    UK

  • Dublin —

    Ireland

  • Sydney —

    Australia

  • Mumbai —

    India

  • Helsingborg —

    Sweden

  • Chicago —

    USA

  • Geneva —

    Switzerland

  • Paris —

    France

London —

UK

Home to our Global Head Office, London is where our Executive Leadership Team is based along with our corporate and operational functions. In total, we have over 100 employees here.

Close ×

Dublin —

Ireland

We have over 10 employees in Dublin who make up our Global Supplier Alliance Management and Ireland Commercial teams.

Close ×

Sydney —

Australia

Our Australasian office is based in Sydney, Australia. It’s where we serve Australia, New Zealand and the Pacific Island countries from. Our 25 employees here work across Business Development, Finance, Regulatory Affairs, Supply Chain and Sales.

Close ×

Mumbai —

India

Shared Service Centre and India Management Team

Close ×

Helsingborg —

Sweden

Business Development, Finance, Quality, Regulatory Affairs, Supply Chain and Sales

Close ×

Chicago —

USA

Clinical Affairs, Commercial, Regulatory, Quality and Finance, legal and supply chain

Close ×

People & Culture

The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help improve the lives of patients by enhancing the critical medicines they depend on.

  • Progressive & Dynamic —

    Our lean and virtual model combined with our responsive and highly experienced teams mean that we are ready to be flexible and adapt to changing situations at a moment’s notice. As a company, we are proud to say we are small enough to care but big enough to make a difference.

  • Unique and Collaborative —

    ADVANZ PHARMA is committed to investing in the growth of our people and rewarding and recognising the contribution they make while providing a unique culture that includes a collaborative and flexible working environment – our people are encouraged to work up to 3 days a week remotely, helping them operate at the very best of their ability while ensuring work life balance.

Ready to join?

Help people lead better lives with medicines, that without our focus, may not be available.

View Careers

Our Values

Our values reflect who we are and what we stand for. Having a purpose, goal and values would mean nothing, however, if we didn’t have the people to bring them to life, to share the journey and vision of building a company we believe in. From London to Mumbai, Helsingborg to Sydney and Geneva to Chicago, resilience and common values have united ADVANZ PHARMA, regardless of geography or remote working situation.

Global Teams

We work together, combining the intellectual power of our global, multicultural workforce to find ways to improve the lives of patients.

Entrepreneurial

We don’t sit back. We constantly strive to create new opportunities that deliver value.

Decision Making

We empower our people to use good judgement to make the right choices, enabling them to grow within the company.

Openness

We believe in open and transparent relationships, both internally and externally. We aim to be accessible to our partners, customers and patients; we strive to deliver the best possible service.

Integrity

We insist on the highest ethical behaviour in all aspects of our work. We operate in a highly complex and competitive environment, but we always aim to do what’s right for the healthcare systems and patients we serve.

Our Commitment —

  • Image for Highest Ethical Standards

    Highest Ethical Standards

    To serve the needs of patients and healthcare providers across the world by operating at the highest ethical standards in all aspects of our work.
    Learn more
  • Image for Accreditation

    Accreditation

    We were re-accredited to BS 10500 in 2017 and in November 2018 we became the first pharma company in the world to achieve ISO37001 accreditation for our comprehensive compliance management
    Learn more
  • Image for Safe and Effective

    Safe and Effective

    We are committed to providing medicines safely and effectively, all to the highest quality standards.
    Learn more
  • Image for Open, Transparent and Collaborative

    Open, Transparent and Collaborative

    We aspire to be open, transparent and collaborative in all our relationships and believe in the power of partnership to build trust and inspire better solutions.
    Learn more

Our Portfolio

At ADVANZ PHARMA, our European hospital portfolio of complex medicines focuses on Anti-infectives, Endocrinology and Critical Care medicines. This is bolstered by an established brands business unit of more than 180 molecules sold into 100 countries across a wide range of therapy areas such as CVD, pain management, ophthalmology, urology, and central nervous system disorders.

Over the years, we have successfully expanded our portfolio through targeted licensing and acquisitions and are well positioned for growth. We continue to work closely with our partners to enhance our medicines and add value through innovation, particularly in the anti-infectives space which has had limited investment in recent years, despite the ever-increasing health burden of antimicrobial resistance.

Our Commitment

  • Our purpose is to help patients lead healthier, better lives by revitalising and innovating niche established medicines that, without our focus, may otherwise not be available.

    But this is not always easy – either because the divestor company has discontinued the manufacture of a medicine and an alternative manufacturer needs to be found or a medicine was originally developed several decades ago which means it can be difficult to manufacture without significant investment to bring it up to date in line with current regulatory requirements.

  • Our experience of supplying and developing niche established medicines for decades means we have a rich heritage of acquiring and investing in these valuable medicines through targeted development, product in-licensing and acquisition to bring them to more markets or by improving product formulation and strength to optimise treatment so that patients can continue to use them for years to come.

  • Bringing medicines to a wider market

    Over the last 15 years, we have acquired more than 15 legacy brands for our international markets and approx. 10 brands for the US market meaning more patients are able to continue to access them.

    Medicines we have revitalized or optimized

    Over the last 10 years, we have worked across 20 initiatives to optimise or revitalize medicines to enhance patient care and provide greater choice.

We have a proud heritage and successful track record of business and product acquisitions and company assets around the world, including BNM in Australia, Focus Pharmaceuticals in the UK, and Abcur in the Nordics an Correvio in Europe.


At ADVANZ PHARMA, we have been supplying and developing niche established medicines for decades and have a rich heritage of acquiring and investing in these medicines so that patients who need them can continue to get them.


Corporate Governance

ADVANZ PHARMA is committed to conducting its business ethically and in compliance with all applicable laws, regulations, guidelines, and policies. ADVANZ PHARMA has established and implemented a Code of Conduct (the “Code”), which sets forth ADVANZ PHARMA's commitment to ethical business conduct.

  • Compliance Officer

    The Compliance Officer is responsible for overseeing the administration and implementation of ADVANZ PHARMA’s compliance program and will report at least quarterly to the Compliance Committee. The Compliance Officer has authority to direct and implement compliance-related changes and to determine the corporate response to compliance-related matters.

  • Compliance Committee

    ADVANZ PHARMA has established a Compliance Committee and the committee meets on a quarterly basis. The Compliance Committee is responsible for ensuring the implementation and effectiveness of the Compliance Program, and to provide advice and support to the Compliance Officer.

  • Compliance Policies

    ADVANZ PHARMA policies and procedures were developed to ensure that interactions with healthcare professionals are appropriate, ethical, and consistent with applicable laws and standards. ADVANZ PHARMA expects its employees to comply with the compliance program, its Code of Conduct, policies, procedures, and all applicable laws. Employees must annually acknowledge their responsibility and commitment to conduct ADVANZ PHARMA’s business consistent with these standards and to report to real or suspect violations. Employees who violate these standards are subject to appropriate disciplinary action, up to and including termination. ADVANZ PHARMA’s policies prohibit retaliation against any employee for making a good faith report.

  • Communicating Compliance & Policies

    ADVANZ PHARMA is committed to an environment in which open communications are encouraged, including questions or concerns about the compliance program. Employees are required to report any activity or individual that is suspect or in violation of the compliance program. Employees may contact direct managers, the Chief Executive Officer, the Chief Financial Officer, the Compliance Officer or the Compliance Committee at compliance@advanzpharma.com or they may use the Compliance Hotline by calling 855-562-5982. The Hotline is available 24 hours a day/7 days a week to allow confidential and anonymous reporting.

  • Monitoring, Auditing & Investigations

    The compliance program includes activities designed to monitor and audit compliance with ADVANZ PHARMA policies and procedures. The Compliance Officer oversees monitoring and auditing through an audit plan, including internal and external auditing activities. The Compliance Officer works with relevant resources to evaluate audit findings and ensure the implementation of any corrective action. The Compliance Officer (or designee) reviews and evaluates concerns to determine the required investigative response.

  • Corrective Action & Discipline

    If it is determined that noncompliant conduct has occurred, appropriate parties are responsible for corrective and/or disciplinary actions. ADVANZ PHARMA’s disciplinary actions may include the following: termination; disciplining any involved employee(s); disciplining supervisor for failure to monitor employees appropriately. ADVANZ PHARMA’s corrective and preventative actions may include: revising the compliance program, policies, and/or procedures; revising the role of the Compliance Committee; increased auditing and monitoring; revising the training program.

  • Updating the Compliance programme

    As ADVANZ PHARMA evolves as a company and as regulations change, it may amend its compliance program. The Compliance Committee reviews and approves all suggested changes. The Compliance Officer shall be responsible for communicating changes in the compliance program to employees.

  • California Compliance Law Declaration

    As part of ADVANZ PHARMA’s continuing commitment to corporate compliance, ADVZ declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Program as mandated by this California law. To the best of our knowledge, as of November 1, 2017, ADVZ believes that it is in compliance with its Comprehensive Compliance Program and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
    Additionally, to comply with California law, ADVZ has established a maximum annual aggregate dollar limit of $1,500 for gifts, promotional materials or activities provided to California health care professionals. This dollar limit represents a spending cap, not a goal or average, and typically the amount spent per physician is anticipated to be substantially less than this maximum amount.
    For questions about our Comprehensive Compliance Program or to obtain a copy, please contact us at compliance@advanzpharma.com.

  • Advanz Pharma AGM 2019

    Form of Proxy

    Circular

    Notice of Meeting

    Voting Instruction Form

    Financial Statements and Management's Discussion and Analysis

Our Leadership Team

  • Graeme Duncan

    Chief Executive Officer —

    Graeme has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the Chief Executive Officer role at ADVANZ PHARMA, Graeme previously served as President of ADVANZ PHARMAs International segment since January 2016. Prior to his role as President, he was Managing Director for ADVANZ PHARMA's International segment.

  • Adeel Ahmad

    Chief Financial Officer —

    Adeel brings over 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the Chief Financial Officer of ADVANZ PHARMA, Adeel was CFO of the Company’s International segment, and before that, Vice President, Finance and Controller of the Company. Prior to joining the company in 2013, Adeel was the Chief Financial Officer of the Indian operations of Ingram Micro Mobility (formerly BrightPoint), based in New Delhi, India, from February 2012 to May 2013. Prior to his role at BrightPoint, Mr. Ahmad held several finance roles of increasing responsibility with Nortel Networks from 2003 to 2012, based in Brampton, Ontario, Canada; Seoul, South Korea; and Beijing, China. Adeel started his career in an audit function with Deloitte LLP in Toronto. He holds a B. Comm from the University of Toronto and an MBA from the Ivey School of Business, University of Western Ontario.

  • Karl Belk

    Chief Operations Officer —

    Karl has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for ADVANZ PHARMA, Karl leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.

  • Guy Clark

    Chief Corporate Development Officer —

    Guy brings to ADVANZ PHARMA more than 25 years of experience in the pharmaceutical industry, including previous senior roles at Glenmark Pharmaceuticals and IVAX Pharmaceuticals. Most recently, he served as Chief Strategy Officer at AMCo Pharmaceuticals from 2013 to 2015. As Chief Corporate Development Officer for ADVANZ PHARMA, Guy focuses on leading the company’s corporate development initiatives including M&A, strategy formulation & implementation and expanding its pipeline of medicines.

  • Simon Tucker

    Chief Commercial Officer, Established Products Unit —

    Simon started his pharmaceutical career as a Medical Representative with Pfizer Ltd in the UK. In 2000 he joined Goldshield and held various International Regional Management positions in the Middle East, Asia and Europe. He then joined the International division of Stiefel Laboratories with particular focus on the Middle East and Africa. Simon joined Amdipharm in 2006 and was instrumental in establishing its Latin American business. In 2011, he became the Director of Alliance Management and in 2013 he was appointed International Commercial Director. As President, International & North America Simon leads our commercial operations in these regions.

  • Paul Burden

    Chief Commercial Officer, Strategic Growth Unit —

    Paul joined ADVANZ PHARMA from Teva in September 2016 in the role of Vice President UK&I Commercial. His diverse commercial career spans 20 years and also includes marketing and commercial strategy roles at Smiths Medical Systems, IVAX Pharmaceuticals, Merck Generics (Mylan) and Arrow Generics (Watson Pharmaceuticals). In 2009 Paul moved into consultancy working as a Director at Fleishman-Hillard (an Omnicom communications consultancy), where he managed international communications programmes for Bristol Myers Squibb and Philips. In 2013, he joined Teva, where he had board level responsibility for the largest generics business in the UK. As President, UK & Ireland and Global Corporate Communications, Paul leads our commercial operations in the region, in addition to leading our Corporate Communications function.

  • Robert Sully

    General Counsel —

    Rob is an experienced General Counsel and corporate lawyer. He worked in London for 11 years for an international law firm before joining AMCo in 2011. As General Counsel during 2011-2016 he ran the legal, company secretarial and corporate communications teams. He was at the forefront of all M&A and he led all post-acquisition integration projects, including the merger of Amdipharm and Mercury Pharma during 2012-13 to create AMCo, and the integrations of Abcur (Sweden), Focus Pharma (UK), Primegen (UK) and BnM (Australia) into AMCo in 2013-2015. He led the integration of the International and North American divisions of Advanz Pharma in 2015-2016 and managed the Group’s regulatory disputes. He was appointed as Global General Counsel in 2018.

  • Fiona Huzarski

    VP, Global HR —

    Fiona Huzarski has worked for over 20 years as a senior HR professional, 15 years within the Pharmaceuticals industry. As Vice President of Global HR, she is responsible for leading the Global HR function and setting the People Strategy to create an inclusive, flexible and collaborative environment where all employees can grow and develop in support of the company’s long-term goals.

    Prior to joining ADVANZ PHARMA as Vice President of Global HR in August 2019, she was Global HR Director at Britannia Pharmaceuticals, part of the STADA group. Her career started in the Management Consulting sector before joining GSK’s Global Recruitment Team and working for 10 years at UCB in various Senior HR roles, supporting the Commercial, R&D and Technical Operations functions in both UK & Ireland and across Europe. She is a Fellow of the Chartered Institute of Personnel & Development (CIPD) and holds a Post graduate Diploma in Human Resource Management from Thames Valley University.

  • Nick Warwick

    Chief Medical Officer —

    Dr Nick Warwick has over 30 years of experience both in the pharmaceutical industry and as a medical doctor. Nick trained as a medical Doctor at Charing Cross Hospital Medical School in London, now part of the Imperial College group, and spent 10 years in clinical medicine rotating through disciplines including emergency medicine, rheumatology and rehabilitation, dermatology, ear nose and throat surgery, obstetrics and gynaecology, and primary care, before joining the Pharmaceutical Industry in 1997 as Medical Adviser for Abbott. In the following 24 years, Nick held senior country level, regional and global leadership roles within Medical Affairs and Clinical Development (Abbott and Abbvie) and was Chief Medical Officer for Sandoz (2014-2019). Nick joined ADVANZ PHARMA as Chief Medical Officer in June 2020. He is responsible for setting the medical vision and strategic direction for the Medical Office (comprising medical affairs, patient safety, clinical development and medical compliance functions), ensuring that ADVANZ PHARMA has the right resources, skills and capabilities to meet its growing business needs and that the voice of the patient and healthcare professional is fully represented in all company decisions.

    Nick holds a Bachelor of Medicine, Bachelor of Surgery from Charing Cross Hospital Medical School, London (MBBS, 1986), and a Diploma from the Royal College of Obstetrics and Gynaecologists, London (DRCOG, 1992) and a Diploma of Pharmaceutical Medicine from the University of Wales, Cardiff (DPM, 1998). He has been a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) since 2010.

  • Graeme Duncan

    Director —

    Graeme has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the interim Chief Executive Officer role at ADVANZ PHARMA, Graeme previously served as President of ADVANZ PHARMA’s International segment since January 2016. Prior to his role as President, he was Managing Director for ADVANZ PHARMA’s International segment.

  • Adeel Ahmad

    Director —

    Mr. Ahmad has more than 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the CFO of ADVANZ PHARMA in June 2018, Mr. Ahmad was CFO of the Company's International segment, and before that, Vice President, Finance and Controller of the Company.

Contact